TITAN PHARMACEUTICALS INC — Director's Dealing 2017

Jan 6, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: TITAN PHARMACEUTICALS INC (TTNP)
CIK: 0000910267
Period of Report: 2017-01-02

Reporting Person: Kumar Rajinder (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$4.00	2027-01-02	Common Stock (25000)		Direct

Footnotes

F1: Vests in 12 equal monthly installments commencing on the date of grant.